



Meeting to commence at 10.30 am on Tuesday, 11th February 2020
in the [Cophthorne Hotel Cardiff](#), Culverhouse Cross, Cardiff CF5 6DH

AGENDA

- | | Enclosure |
|---|--------------|
| 1. Welcome and introduction | |
| 2. Apologies | |
| 3. Declarations of interest | |
| 4. Minutes of previous meeting | 1/AWMSG/0220 |
| 5. Chairman's report (verbal update) | |
| 6. Feedback from AWPAG Meeting held 4th December 2019 | 2/AWMSG/0220 |
| 7. National Prescribing Indicators 2020–2021 | 3/AWMSG/0220 |
| Supporting Information for Prescribers and Healthcare Professionals | 4/AWMSG/0220 |
| 8. National Prescribing Indicators 2019–2020 : Analysis of Prescribing Data to September 2019 | 5/AWMSG/0220 |
| 9. Appraisal 1: Limited Submission (orphan medicine) | 6/AWMSG/0220 |
| Plerixafor (Mozobil®) In combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children aged 1 to less than 18 years with lymphoma or solid malignant tumours, either: pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with G-CSF (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield; or who previously failed to collect sufficient haematopoietic stem cells. | Appendices |
| <i>To protect commercial confidentiality the following appraisal will be held in private and individuals seated in the public gallery will be asked to leave the meeting</i> | |
| 10. Appraisal 2: Limited Submission (WPAS) | 7/AWMSG/0220 |
| Dolutegravir/lamivudine (Dovato®) for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine | Appendices |

***Following the appraisal session members will retire to vote
The meeting will open to the public and the Chair will
announce the appraisal recommendations***

11. **All Wales Advice on Oral Anticoagulation for Non-valvular Atrial Fibrillation** 8/AWMSG/0220
12. **Items Identified as Low Priority for Funding in NHS Wales (Paper 3)** 9/AWMSG/0220
13. **National Guiding Principles for Medicines Support in the Domiciliary Care Sector** 10/AWMSG/0220
14. **Any other business**

Date of next meeting – Tuesday, 17th March 2020 in Cardiff